Opinion|Videos|December 24, 2024
Unmet Needs in IPF- and ILD-Related Pulmonary Hypertension and Emerging Therapy for IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses additional noteworthy data from CHEST 2024 on emerging therapies for IPF and PAH and highlights his excitement for ongoing research focused on improving early detection, personalized treatments, and improving long-term patient outcomes.
Advertisement
Episodes in this series
- Please discuss any other data in IPF or PAH released at CHEST 2024 that you find noteworthy to share with colleagues.
- Outside of CHEST 2024, what ongoing research efforts are you most excited about in the treatment and management of IPF and PAH, and what are some key areas where you think further research is needed to continue improving patient outcomes?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
2
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
3
First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
4
5 Notable Oncology FDA Approvals Granted in May
5